Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
European Commission seeks biopharma feedback on Novo-Catalent deal — report
6 months ago
Manufacturing
Merck buys into PD-1/VEGF space as Summit comes for Keytruda
6 months ago
China
Pharma
Otsuka and ICU Medical forge IV manufacturing network to supply the US
6 months ago
Manufacturing
New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug
6 months ago
China
Pharma
Roche teams with Flare Therapeutics on transcription factors
6 months ago
Startups
Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use
6 months ago
R&D
Pharma
GSK snags Parkinson's drug from Flagship startup Vesalius
6 months ago
Startups
Pharma
Cigna says it will not pursue a merger with Humana
6 months ago
Health Tech
Danish company pays $145M upfront to license nasal spray alternative to EpiPen
6 months ago
Pharma
Avid Bioservices to be sold to private equity firms for $1.1B
6 months ago
Manufacturing
Joe Jimenez's latest Aditum company lines up T cell engager from China
6 months ago
Startups
China
PrognomiQ raises $34M for lung cancer test
6 months ago
Diagnostics
Nektar divests manufacturing site and reagent arm for $90M
6 months ago
Manufacturing
European Commission marks Dec. 6 for Novo-Catalent deal decision
6 months ago
Manufacturing
Q&A: Jade CEO talks about reverse merger and IgAN drugs
6 months ago
Startups
AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M
6 months ago
Startups
Pharma
Another Paragon offshoot inks reverse merger as Jade takes Aerovate’s place
6 months ago
Startups
Lundbeck doubled its offer for Longboard over six months, new filing shows
6 months ago
Biogen signs molecular glue deal, raises yearly projections
6 months ago
R&D
Pharma
Novartis highlights overall M&A track record following MorphoSys impairment
6 months ago
Pharma
GSK buys autoimmune T cell engager for $300M upfront from Chimagen
6 months ago
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger
6 months ago
Corrected: Genmab lines up T cell engager pact with Revitope
6 months ago
Startups
Pharma
Novartis takes $800M MorphoSys writedown mere months after closing acquisition
6 months ago
R&D
Pharma
First page
Previous page
7
8
9
10
11
12
13
Next page
Last page
